Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Open Access
- 16 March 2010
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 17 (3), 249-261
- https://doi.org/10.1016/j.ccr.2010.01.021
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1Journal of Biological Chemistry, 2009
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2PLoS Biology, 2009
- Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiencyNature, 2008
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translationProceedings of the National Academy of Sciences of the United States of America, 2008
- Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formationJCI Insight, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- mTORC1 promotes survival through translational control of Mcl-1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Akt1 and Akt2 are required for αβ thymocyte survival and differentiationProceedings of the National Academy of Sciences of the United States of America, 2007
- The Akt of translational controlOncogene, 2005
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002